Catalyst Pharmaceuticals (CPRX) Enterprise Value (2016 - 2025)
Historic Enterprise Value for Catalyst Pharmaceuticals (CPRX) over the last 16 years, with Q3 2025 value amounting to -$689.9 million.
- Catalyst Pharmaceuticals' Enterprise Value fell 5596.74% to -$689.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$689.9 million, marking a year-over-year decrease of 5596.74%. This contributed to the annual value of -$517.6 million for FY2024, which is 27603.03% down from last year.
- Latest data reveals that Catalyst Pharmaceuticals reported Enterprise Value of -$689.9 million as of Q3 2025, which was down 5596.74% from -$652.8 million recorded in Q2 2025.
- In the past 5 years, Catalyst Pharmaceuticals' Enterprise Value ranged from a high of -$121.0 million in Q3 2023 and a low of -$689.9 million during Q3 2025
- Its 5-year average for Enterprise Value is -$304.9 million, with a median of -$220.8 million in 2022.
- As far as peak fluctuations go, Catalyst Pharmaceuticals' Enterprise Value surged by 5387.46% in 2023, and later plummeted by 27603.03% in 2024.
- Catalyst Pharmaceuticals' Enterprise Value (Quarter) stood at -$191.3 million in 2021, then crashed by 56.01% to -$298.4 million in 2022, then surged by 53.87% to -$137.6 million in 2023, then plummeted by 276.03% to -$517.6 million in 2024, then tumbled by 33.3% to -$689.9 million in 2025.
- Its Enterprise Value was -$689.9 million in Q3 2025, compared to -$652.8 million in Q2 2025 and -$580.7 million in Q1 2025.